Anoro Ellipta (umeclidinium/vilanterol) is a brand-name drug that’s prescribed for chronic obstructive pulmonary disease (COPD) in adults. Anoro Ellipta comes as an ...
The cost of Anoro Ellipta can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Anoro Ellipta. Save up to $17 ...
Anoro Ellipta (umeclidinium/vilanterol) is a prescription drug that’s used to treat chronic obstructive pulmonary disease (COPD). Anoro Ellipta can interact with ...
RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (lse/nyse:GSK) and Theravance, Inc. THRX +1.96% today announced that Anoro™ Ellipta® ...
ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ANORO™ ELLIPTA ...
LONDON — GlaxoSmithKline and Theravance on Monday announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder), a once-daily that combines two long-acting bronchodilators in a single ...
Anoro(R) (Umeclidinium/Vilanterol) Gains Marketing Authorisation in Europe for the Treatment of COPD
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - May 8, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European ...
Anoro Ellipta (umeclidinium/vilanterol) is a prescription drug used to treat chronic obstructive pulmonary disease (COPD) in adults. Anoro Ellipta comes in one ...
Anoro Ellipta combines umeclidinium 62.5mcg, a long-acting muscarinic antagonist, and vilanterol 25mcg, a long-acting beta2-agonist (LABA). Umeclidinium exerts its effect through inhibition of M3 ...
RESEARCH TRIANGLE PARK, NC and SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 28, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that Anoro™ ...
RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that Anoro™ Ellipta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results